Targets › FFAR4
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 3; Psychiatry, Infectious disease; next expected readout Dec 2026.
[Isoform 2]: G protein-coupled receptor for long-chain fatty acids (LCFAs) with a major role in adipogenesis, energy metabolism and inflammation. Signals via G protein and beta-arrestin pathways. (UniProt, Q5NUL3)
Open in Phaseline: the race on FFAR4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Samuel Fortin | Monoglyceride Eicosapentaenoic acid (MAG-EPA) Omega-3 fatty acid that activates free fatty acid receptors and reduces inflammation throu | FFAR1, FFAR4 | Phase 4 | Brain Fog | May 2027 |
| Ottawa Heart Institute Research Corporation | Icosapent Ethyl (Vascepa) Triglyceride-lowering agent; omega-3 fatty acid | FFAR1, FFAR4 | Phase 3 | Inflammation | Dec 2026 |
Brain Fog (1) Inflammation (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.